industry

The company sees Q1 sales of $354-$356 million vs a Street target of $354 million. Gross margins are expected to be approximately 64%.

Equinix (NASDAQ:EQIX) reported Q4 EPS of 29 cents, topping consensus estimates of 23 cents. Revenue totaled $345.2 million, inline with Street estimates.

Cisco reported adjusted inventory turns of 10.0 and days sales outstanding of 40 days. That is is up from 38 days during Q1.

Chairman and CEO John Chamber said, "The quarter played out as we expected. Our strategy of tightly integrating our multiple products through an architectural approach is working, and we are delivering innovation in each major pro

Cisco (NASDAQ:CSCO) reported fiscal Q2 EPS of 37 cents, topping consensus estimates of 35 cents. Sales in the quarter totaled $10.41 billion, above the Street estimate of $10.24 billion.

Teva said results from a Phase III study of QNAZE HFA, its nasal aerosol corticosteroid in development to treat perennial allergic rhinitis (PAR) and seasonal allergic rhinitis, achieved all primary and secondary efficacy endpoint

Teva shares are down 0.9%, or $0.46, to $51.56.

Teva Pharmaceuticals (TEVA) shares are down fractionally, despite positive drug trial news.

The bank sees 2011 EPS of $0.77, down from $0.86 per share, and 2012 EPS of $1.28, up from $1.12 per share.

OpenTable is currently above its 50-day moving average (MA) of $75.14 and above its 200-day of $57.89.

Morgan Stanley adjusted its 2011 and 2012 EPS estimates for OpenTable (NASDAQ:OPEN) and maintained its equal-weight rating.

The company posted record revenue of $33.8 million for the fourth quarter ended Dec. 31, a 29% increase over the $26.2 million reported for the same period in 2009. Net income was $4.3 million for the fourth quarter, or $0.20 per

Shares of Stratasys (SSYS) are up $4.80 to $40.18, or 11.61%, after the company reported strong fourth quarter and full year financial results that surpassed market expectations.

Morgan Stanley lowered its 2011 and 2012 EPS estimates for Teva Pharmaceutical Industries (NASDAQ:TEVA) and maintained its equal-weight rating. The bank sees 2011 EPS of $5.05, down from $5.29 per share, and 2012 EPS of $5.78, do

Revenue Cycle Manager enables error correction at every stage, unlike legacy applications that resolve errors at the end-stages of the revenue cycle, or point solutions that take limiting approaches at some stages, the company sai

Shares are down 0.36% or $38.47.

Pegasystems (PEGA) today announced the launch of its new Revenue Cycle Manager solution for the health care market, which it says allows health care systems to streamline patient billing, boost cash flow and drive down operational